UK markets open in 1 hour 58 minutes

ADC Therapeutics SA (ADCT)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
4.4400-0.3400 (-7.11%)
At close: 04:00PM EDT
4.5000 +0.06 (+1.35%)
After hours: 07:36PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.7800
Open4.6500
Bid0.0000 x 800
Ask0.0000 x 800
Day's range4.4100 - 4.6500
52-week range0.3600 - 6.0400
Volume295,796
Avg. volume713,674
Market cap366.431M
Beta (5Y monthly)1.74
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs of anti-tumor activity Enrollment in Part 2 dose expansion has been initiated LAUSANNE, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYN

  • GlobeNewswire

    ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

    LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT. The event will feature presentations from Ameet Mallik, Chief Executive Officer, and Patrick van Berkel, PhD, Chief Scientific Officer, highlighting recent updates and the Company’s novel exatecan-based antibody drug conjugate platform. A live question and answer session will

  • Globe Newswire

    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

    LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company’s common shares to six new employees on April 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan